FIDIA SPA (FDA.MI) Fundamental Analysis & Valuation

BIT:FDA • IT0005654683

0.055 EUR
-0.01 (-9.98%)
Last: Mar 5, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This FDA.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Overall FDA gets a fundamental rating of 1 out of 10. We evaluated FDA against 107 industry peers in the Machinery industry. FDA has a bad profitability rating. Also its financial health evaluation is rather negative. FDA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. FDA.MI Profitability Analysis

1.1 Basic Checks

  • FDA had negative earnings in the past year.
  • In the past year FDA had a positive cash flow from operations.
  • In the past 5 years FDA reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: FDA reported negative operating cash flow in multiple years.
FDA.MI Yearly Net Income VS EBIT VS OCF VS FCFFDA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

  • The Return On Assets of FDA (-8.49%) is worse than 84.11% of its industry peers.
  • Looking at the Return On Equity, with a value of -53.14%, FDA is doing worse than 85.98% of the companies in the same industry.
Industry RankSector Rank
ROA -8.49%
ROE -53.14%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FDA.MI Yearly ROA, ROE, ROICFDA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

  • FDA has a Gross Margin of 69.64%. This is amongst the best in the industry. FDA outperforms 94.39% of its industry peers.
  • In the last couple of years the Gross Margin of FDA has grown nicely.
  • FDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.42%
GM growth 5Y4.76%
FDA.MI Yearly Profit, Operating, Gross MarginsFDA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. FDA.MI Health Analysis

2.1 Basic Checks

  • FDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for FDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FDA.MI Yearly Shares OutstandingFDA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20K 40K 60K
FDA.MI Yearly Total Debt VS Total AssetsFDA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

  • FDA has an Altman-Z score of 0.07. This is a bad value and indicates that FDA is not financially healthy and even has some risk of bankruptcy.
  • FDA has a Altman-Z score of 0.07. This is in the lower half of the industry: FDA underperforms 77.57% of its industry peers.
  • The Debt to FCF ratio of FDA is 6.13, which is on the high side as it means it would take FDA, 6.13 years of fcf income to pay off all of its debts.
  • FDA has a Debt to FCF ratio (6.13) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 1.41 is on the high side and indicates that FDA has dependencies on debt financing.
  • With a Debt to Equity ratio value of 1.41, FDA is not doing good in the industry: 83.18% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.41
Debt/FCF 6.13
Altman-Z 0.07
ROIC/WACCN/A
WACC8.13%
FDA.MI Yearly LT Debt VS Equity VS FCFFDA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

2.3 Liquidity

  • FDA has a Current Ratio of 1.06. This is a normal value and indicates that FDA is financially healthy and should not expect problems in meeting its short term obligations.
  • FDA has a Current ratio of 1.06. This is in the lower half of the industry: FDA underperforms 77.57% of its industry peers.
  • FDA has a Quick Ratio of 1.06. This is a bad value and indicates that FDA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.46, FDA is not doing good in the industry: 90.65% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 0.46
FDA.MI Yearly Current Assets VS Current LiabilitesFDA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. FDA.MI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 70.56% over the past year.
  • Looking at the last year, FDA shows a very negative growth in Revenue. The Revenue has decreased by -27.40% in the last year.
  • Measured over the past years, FDA shows a very negative growth in Revenue. The Revenue has been decreasing by -17.51% on average per year.
EPS 1Y (TTM)70.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.95%
Revenue 1Y (TTM)-27.4%
Revenue growth 3Y-9.81%
Revenue growth 5Y-17.51%
Sales Q2Q%38.18%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FDA.MI Yearly Revenue VS EstimatesFDA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
FDA.MI Yearly EPS VS EstimatesFDA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 0 50 -50

More info and screens

Find the best growth stocksShow best growing peers

2

4. FDA.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FDA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FDA.MI Price Earnings VS Forward Price EarningsFDA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • FDA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. FDA is cheaper than 99.07% of the companies in the same industry.
Industry RankSector Rank
P/FCF 1.5
EV/EBITDA N/A
FDA.MI Per share dataFDA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FDA.MI Dividend Analysis

5.1 Amount

  • FDA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FDA.MI Fundamentals: All Metrics, Ratios and Statistics

FIDIA SPA

BIT:FDA (3/5/2026, 7:00:00 PM)

0.055

-0.01 (-9.98%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners1.46%
Ins Owner ChangeN/A
Market Cap1.67M
Revenue(TTM)21.08M
Net Income(TTM)-2.19M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.08
P/FCF 1.5
P/OCF 1.31
P/B 0.4
P/tB 0.46
EV/EBITDA N/A
EPS(TTM)-6.13
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY66.85%
OCF(TTM)0.04
OCFY76.57%
SpS0.7
BVpS0.14
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.49%
ROE -53.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.64%
FCFM 5.28%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.42%
GM growth 5Y4.76%
F-Score5
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 1.41
Debt/FCF 6.13
Debt/EBITDA N/A
Cap/Depr 12.72%
Cap/Sales 0.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 0.46
Altman-Z 0.07
F-Score5
WACC8.13%
ROIC/WACCN/A
Cap/Depr(3y)19.7%
Cap/Depr(5y)16.39%
Cap/Sales(3y)1.17%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-27.4%
Revenue growth 3Y-9.81%
Revenue growth 5Y-17.51%
Sales Q2Q%38.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-112.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.73%
OCF growth 3YN/A
OCF growth 5YN/A

FIDIA SPA / FDA.MI FAQ

What is the ChartMill fundamental rating of FIDIA SPA (FDA.MI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to FDA.MI.


What is the valuation status for FDA stock?

ChartMill assigns a valuation rating of 2 / 10 to FIDIA SPA (FDA.MI). This can be considered as Overvalued.


How profitable is FIDIA SPA (FDA.MI) stock?

FIDIA SPA (FDA.MI) has a profitability rating of 2 / 10.